John, Thomas
Majem, Margarita
Legg, Diane
Goldman, Jonathan
Funding for this research was provided by:
AstraZeneca
Article History
Accepted: 25 October 2022
First Online: 19 December 2022
Declarations
:
: This publication was funded by AstraZeneca, Cambridge, UK.
: Thomas John reports advisory board and consultancy fees from Roche AG, Bristol-Myers Squibb, Merck & Co., Ignyta, AstraZeneca, Takeda Pharmaceutical, MSD, Specialised Therapeutics, and Pfizer Inc. Margarita Majem reports speaker’s bureau and advisory board fees from Amgen, Sanofi, Pfizer, Janssen, Bristol-Myers Squibb, MSD, Boehringer Ingelheim, AstraZeneca, Roche AG, Kyowa Kyrin, Pierre Fabre, Takeda Pharmaceutical, and Bayer AG, and has received research grants from Bristol-Myers Squibb, AstraZeneca, and Roche AG. Diane Legg has no conflicts of interest to declare. Jonathan Goldman reports research grants from Array, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Genentech/Roche, Janssen, Merck, Pfizer, and Puma, and honoraria from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Genentech, and Pfizer Inc.
: The ADAURA study (NCT02511106) was conducted in accordance with the provisions of the Declaration of Helsinki, Good Clinical Practice guidelines (as defined by the International Conference on Harmonisation), applicable regulatory requirements, and the policy on bioethics and human biologic samples of the trial sponsor, AstraZeneca.
: All patients provided informed written consent prior to participation.
: Not applicable.
: Not applicable.
: All named authors meet the International Committee of Medical Journal Editors criteria for authorship of this outline and take responsibility for the integrity of the work as a whole. The authors acknowledge Rachel Gater, PhD, of Ashfield MedComms, an Inizio Company, for medical writing support that was funded by AstraZeneca in accordance with Good Publications Practice (GPP) guidelines (ExternalRef removed).